LIBERATE Patients from Emphysema!

PITTSBURGH. (Ivanhoe Newswire) -- More than four million Americans have emphysema, a chronic lung disease that makes it impossible to take a full breath. Major surgery to remove the damaged part of the lung or a lung transplant used to be the best options for some patients with advanced cases. Now, doctors at 17 sites nationwide are testing a minimally- invasive procedure that may save lives.
Source: Medical Headlines From Ivanhoe.com - Category: Consumer Health News Source Type: news

Related Links:

Authors: Hosseinirad H, Rashidi M, Moghaddam MM, Tebyanian H, Nouraei S, Mirhosseini SA, Rasouli M, Habibian S Abstract The respiratory system is a complex group of organs in the human body, all of which are necessary in breathing. Due to its special anatomy and composition, after exposure to various damaging factors such as micro particles, carbon granules and toxic gases, the respiratory system can be affected by a variety of damage without return to its original state. Currently, the prevalence of lung diseases, including asthma, and chronic obstructive pulmonary diseases, such as emphysema, has increased remark...
Source: Cellular and Molecular Biology - Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research
Publication date: Available online 4 July 2018Source: The Lancet Respiratory MedicineAuthor(s): Hyun-Kyoung Koo, Dragoş M Vasilescu, Steven Booth, Aileen Hsieh, Orestis L Katsamenis, Nick Fishbane, W Mark Elliott, Miranda Kirby, Peter Lackie, Ian Sinclair, Jane A Warner, Joel D Cooper, Harvey O Coxson, Peter D Paré, James C Hogg, Tillie-Louise HackettSummaryBackgroundThe concept that small conducting airways less than 2 mm in diameter become the major site of airflow obstruction in chronic obstructive pulmonary disease (COPD) is well established in the scientific literature, and the last generation of small conduct...
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
Publication date: 2018Source: Respiratory Medicine Case Reports, Volume 25Author(s): Pradnya D. Patil, Samir Sultan, M. Frances Hahn, Sreeja Biswas Roy, Mitchell D. Ross, Hesham Abdelrazek, Ross M. Bremner, Nitika Thawani, Rajat Walia, Tanmay S. PanchabhaiAbstractPatients under consideration for lung transplantation as treatment for end-stage lung diseases such as idiopathic pulmonary fibrosis (IPF) often have risk factors such as a history of smoking or concomitant emphysema, both of which can predispose the patient to lung cancer. In fact, IPF itself increases the risk of lung cancer development by 6.8% to 20%. Solid org...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
Publication date: Available online 4 July 2018Source: The Lancet Respiratory MedicineAuthor(s): Hyun-Kyoung Koo, Dragoş M Vasilescu, Steven Booth, Aileen Hsieh, Orestis L Katsamenis, Nick Fishbane, W Mark Elliott, Miranda Kirby, Peter Lackie, Ian Sinclair, Jane A Warner, Joel D Cooper, Harvey O Coxson, Peter D Paré, James C Hogg, Tillie-Louise HackettSummaryBackgroundThe concept that small conducting airways less than 2 mm in diameter become the major site of airflow obstruction in chronic obstructive pulmonary disease (COPD) is well established in the scientific literature, and the last generation of small conduct...
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
Publication date: 2018Source: Respiratory Medicine Case Reports, Volume 25Author(s): Pradnya D. Patil, Samir Sultan, M. Frances Hahn, Sreeja Biswas Roy, Mitchell D. Ross, Hesham Abdelrazek, Ross M. Bremner, Nitika Thawani, Rajat Walia, Tanmay S. PanchabhaiAbstractPatients under consideration for lung transplantation as treatment for end-stage lung diseases such as idiopathic pulmonary fibrosis (IPF) often have risk factors such as a history of smoking or concomitant emphysema, both of which can predispose the patient to lung cancer. In fact, IPF itself increases the risk of lung cancer development by 6.8% to 20%. Solid org...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
FDA has approved a new device intended to treat breathing difficulty associated with severe emphysema. The approval comes just two weeks after an FDA advisory panel shot down a competing technology targeting the same patient population. The agency approved Pulmonx Inc.'s Zephyr endobronchial valve through the breakthrough device designation, a pathway reserved for devices that provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. Devices also must meet one of the following criteria: the device must represent a breakthrough technology; there must be no app...
Source: MDDI - Category: Medical Devices Authors: Tags: Regulatory and Compliance Source Type: news
The FDA approved a new medical device for patients suffering from severe emphysema. The Pulmonx Zephyr Endobronchial Valve is a one-way valve system to be implanted through the airways using a traditional bronchoscope. The valve is integrated into a ...
Source: Medgadget - Category: Medical Devices Authors: Tags: Medicine Thoracic Surgery Source Type: blogs
The FDA today granted pre-market approval under its breakthrough devices designation to the Zephyr endobronchial valve made by Pulmonx for treating severe emphysema. Emphysema, a chronic obstructive pulmonary disease, causes irreversible damage to the lung’s alveoli, trapping air during exhalation that in turn can cause the diseased tissue to grow larger and pressure healthy lung tissue. The Zephyr device is designed to decrease the volume of the chest to improve function in the heart, respiratory muscles and healthy lung tissue. Inserted via bronchoscopy, the pencil-eraser-sized valves prevent air from ent...
Source: Mass Device - Category: Medical Devices Authors: Tags: Endoscopic / Arthroscopic Food & Drug Administration (FDA) Regulatory/Compliance Respiratory Pulmonx Source Type: news
Publication date: 2018 Source:Respiratory Medicine Case Reports, Volume 25 Author(s): Pradnya D. Patil, Samir Sultan, M. Frances Hahn, Sreeja Biswas Roy, Mitchell D. Ross, Hesham Abdelrazek, Ross M. Bremner, Nitika Thawani, Rajat Walia, Tanmay S. Panchabhai Patients under consideration for lung transplantation as treatment for end-stage lung diseases such as idiopathic pulmonary fibrosis (IPF) often have risk factors such as a history of smoking or concomitant emphysema, both of which can predispose the patient to lung cancer. In fact, IPF itself increases the risk of lung cancer development by 6.8% to 20%. Solid organ ma...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
Abstract This brief imaging case report highlights a successful bridge to lung transplantation after endobronchial coil assisted lung volume reduction procedure. Our patient was a 64-year-old male with severe emphysema (FEV1:19%, RV: 289%, TLC: 143%), on maximum medical regimen who was enrolled into the Lung Volume Reduction Coil Treatment (RENEW) Study. He underwent bilateral endobronchial coil placement in a two-step procedure, with an immediate improvement in symptoms and pulmonary function testing (FEV1:21%, RV: 254%, TLC: 138%). The need for lung transplantation was delayed by three and half years because of ...
Source: American Journal of Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Tags: Am J Respir Crit Care Med Source Type: research
More News: Emphysema | Health | Lung Transplant | Transplant Surgery | Transplants